Co-Diagnostics, Inc. — fact timeline

Co-Diagnostics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at aggregate gross proceeds of $3.0 million (effective 2026-05-19).

“On May 19, 2026, Co-Diagnostics, Inc. (the “Company”), entered into a private placement transaction (the “Private Placement”), pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”) for aggregate gross proceeds of $3.0 million”

Co-Diagnostics, Inc. reported first quarter ended March 31, 2026 results: revenue $0.15 million, net income Net loss of $9.1 million, or $4.06 per share, EPS $4.06 per share.

“global stakeholders ● Expanded the intellectual property portfolio with the issuance of a new international patent in Japan First Quarter 2026 Financial Results: ● Revenue of $0.15 million, compared to $0.05 million in the first quarter of 2025 ● Operating expenses of $9.2 million, compared to $8.6 million in the same period last year, driven by research and”

Co-Diagnostics, Inc. reported full year ended December 31, 2025 results: revenue $0.6 million, net income net loss of $46.9 million, EPS $35.25 per share.

“the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results: ● Revenue of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue ● Operating expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment”

Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).

“January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi”

Co-Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 10, 2025, Co-Diagnostics, Inc. (“CODX” or “the Company”) received a notice from Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Company has a period of 180 calendar days, or until July 9, 2025 (the “Compliance Date”), to regain compliance with Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s com”

Co-Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 10, 2025, Co-Diagnostics, Inc. (“CODX” or “the Company”) received a notice from Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price”

Co-Diagnostics, Inc. reported quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss of $9.3 million, EPS loss of $0.31 per fully diluted share.

“Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3 million ● Operating expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for the development of tests currently in our pipeline ● Operating loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 ● Net loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share, compared to a loss of $0.20 per fully dilut”

Richard Abbott was appointed as President at Co-Diagnostics, Inc..

“On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.”

Co-Diagnostics, Inc. reported the full year ended December 31, 2023 results: revenue $6.8 million, net income Net loss of $35.3 million, EPS a loss of $1.20 per fully diluted share.

“the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023. Full Year 2023 Financial Results: ● Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests. Grant revenue totaled $5.8 million while”

Co-Diagnostics, Inc. reported quarter ended September 30, 2023 results: revenue $2.5 million, net income $6.0 million, EPS $0.20 per fully diluted share.

“the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Results: ● Revenue of $2.5 million, down from $5.1 million during the prior year primarily due to the anticipated decline in global demand for COVID-19 tests. Grant revenue totaled $2.3 million while product”

Co-Diagnostics, Inc. shareholders approved Ratification of the Audit Committee's appointment of Tanner LLC as the Company's independent registered public accounting firm for the year ending December 31, 2023. at the 2023-08-30 meeting.

“Proposal No. 3 : A proposal to ratify the Audit Committee’s appointment of Tanner LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2023. This proposal was ratified.”

Co-Diagnostics, Inc. shareholders approved Adoption, on an advisory basis, of a non-binding resolution approving the compensation of the Company's named executive officers. at the 2023-08-30 meeting.

“Proposal No. 2 : A proposal to adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement under “Executive Compensation.” This proposal was adopted.”

Co-Diagnostics, Inc. shareholders approved Election of two Class II directors to hold office for a term expiring at the annual meeting of stockholders to be held in 2026 or until their respective successors are elected and qualified. at the 2023-08-30 meeting.

“Proposal No. 1 : A proposal to elect two Class II directors to hold office for a term expiring at the annual meeting of stockholders to be held in 2026 or until their respective successors are elected and qualified. This proposal was approved and Messrs. Egan and Durenard were elected to the board of directors of the Company.”

Co-Diagnostics, Inc. reported second quarter 2023 results: revenue $0.2 million, net income Net loss of $8.9 million, EPS EPS loss of $0.31 per fully diluted share.

“the development of molecular diagnostic tests, announced today financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Results: ● Revenue of $0.2 million, down from $5.0 million during the prior year primarily due to the anticipated decline in global demand for the Logix Smart® COVID-19 tests ● Operating expenses of $11.7”

Co-Diagnostics, Inc. reported first quarter ended March 31, 2023 results: revenue $0.6 million, net income $5.8 million, EPS $0.20 per fully diluted share.

“First Quarter 2023 Financial Results: ● Revenue of $0.6 million, down from $22.7 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $0.1 million, representing 16.6% of consolidated revenue ● Operating loss of $10.0 million compared to operating income of $9.8 million a year ago, due to lower revenue and continued investments into research and development for the Co-Dx PCR HomeTM Platform ● Net loss of $5.8 million, compared to net income of $11.7 million in the prior year, representing EPS loss of $0.20 per fully diluted share”

Co-Diagnostics, Inc. dismissed Haynie & Company as its auditor.

“Haynie & Company (“Haynie”), the Company’s independent registered public accounting firm prior to the appointment of Tanner, will be dismissed effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 and replaced by Tanner as the Company’s independent registered public accounting firm.”

Co-Diagnostics, Inc. engaged Tanner LLC as its auditor.

“On March 31, 2023, the Audit Committee of Co-Diagnostics, Inc.’s (the “Company”) Board of Directors approved the engagement of Tanner LLC (“Tanner”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023.”

Co-Diagnostics, Inc. reported the full year ended December 31, 2022 results: revenue $34.2 million, net income $14.2 million, EPS $0.45 per fully diluted share.

“the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. Full Year 2022 Financial Results: ● Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $28.7 million, representing 84.0% of”

Co-Diagnostics, Inc. reported the third quarter ended September 30, 2022 results: revenue Revenue of $5.1 million, net income Net loss of $1.4 million, EPS loss of $0.04 per fully diluted share.

“development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: ● Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter ● Gross profit of $4.3 million, representing 84.9% of”

Brian L. Brown was appointed as Corporate Secretary at Co-Diagnostics, Inc..

“the Company’s Board of Directors appointed Brian L. Brown, CPA, as the Company’s Corporate Secretary.”

Reed L. Benson resigned as Corporate Secretary at Co-Diagnostics, Inc..

“Mr. Reed L. Benson resigned as the Corporate Secretary of Co-Diagnostics, Inc.”